SEARCH

SEARCH BY CITATION

References

  • 1
    D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 33254.
  • 2
    North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices T. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319: 9839.
  • 3
    Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003; 361: 9524.
  • 4
    Christensen E, Fauerholdt L, Schlichting P, Juhl E, Poulsen H, Tygstrup N. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 1981; 81: 94452.
  • 5
    Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003; 98: 6539.
    Direct Link:
  • 6
    Triantos CK, Burroughs AK. Prevention of the development of varices and first portal hypertensive bleeding episode. Best Pract Res Clin Gastroenterol 2007; 21: 3142.
  • 7
    Hobolth L, Krag A, Bendtsen F. The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5. Liver Int 2010; 30: 45562.
  • 8
    Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010; 32: 85971.
  • 9
    Schmitz RJ, Sharma P, Badr AS, Qamar MT, Weston AP. Incidence and management of esophageal stricture formation, ulcer bleeding, perforation, and massive hematoma formation from sclerotherapy versus band ligation. Am J Gastroenterol 2001; 96: 43741.
    Direct Link:
  • 10
    Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007; 102: 28428.
    Direct Link:
  • 11
    Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123: 2807.
  • 12
    De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 7628.
  • 13
    Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding–unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology 2008; 47: 176472.
  • 14
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 92238.
  • 15
    Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008; 149: 10922.
  • 16
    Ravipati M, Katragadda S, Swaminathan PD, Molnar J, Zarling E. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc 2009; 70: 65864 e5.
  • 17
    Funakoshi N, Segalas-Largey F, Duny Y, et al. Benefit of combination beta-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010; 16: 598292.
  • 18
    Cheung J, Zeman M, Van Zanten SV, Tandon P. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharmacol Ther 2009; 30: 57788.
  • 19
    Gluud LL. Bias in clinical intervention research. Am J Epidemiol 2006; 163: 493501.
  • 20
    Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 6018.
  • 21
    Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 6475.
  • 22
    Cheng W-F, Shi R-H, Chen X-X, Ding J. Effects of propranolol on rebleeding following endoscopic esophageal variceal ligation: a prospective, controlled trial. World Chin J Digesto 2009; 17: 835.
  • 23
    Gonzalez A, Augustin S, Perez M, et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 2006; 44: 80612.
  • 24
    Villanueva C, Aracil C, Colomo A, et al. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther 2009; 29: 397408.
  • 25
    Um SH, Yeon SS. Endoscopic Band Ligation (EBL) versus endoscopic band ligation and propranolol for the prevention of variceal rebleeding in pts with previous variceal treatment. Available at: http://www.clinicaltrials.gov; 2009.
  • 26
    Abdel-Rahim AY, Abdel-Ghany MS, El-Kholy B. Band ligation alone versus band ligation and propranolol in the management of bleeding oesophageal varices. Kasr El Aini Medical Journal 1999; 5: 15166.
  • 27
    Abdel-Rahim AY, Abdel-Ghany MS, El-Kholy B. Band ligation alone versus band ligation and propranolol in the management of bleeding oesophageal varices. Am J Gastroenterol 2000; 95: 2442.
    Direct Link:
  • 28
    Ahmad I, Khan AA, Alam A, Butt AK, Shafqat F, Sarwar S. Propranolol, isosorbide mononitrate and endoscopic band ligation - alone or in varying combinations for the prevention of esophageal variceal rebleeding. J Coll Physicians Surg Pak 2009; 19: 2836.
  • 29
    De la Pena J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 5728.
  • 30
    De la Pena J, Rivero M, Garcia Suarez C, et al. Variceal ligation plus nadolol compared with variceal ligation after bleeding: multicenter randomized trial preliminary analysis. Gastroenterology 2003; 124: S1538A.
  • 31
    Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009; 58: 114450.
  • 32
    Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol+Isosorbide-5-mononitrate (NAD+ISMN) vs NAD+ISMN + endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis. Preliminary results of a multicenter RCT. J Hepatol 2006; 44(Suppl. 2): S112.
  • 33
    Jain A, Kumar A, Tyagi P, Sharma BC, Sarin SK. Endoscopic Variceal Ligation (EVL) plus Propranolol (P) and Isosorbide Mononitrate (ISMN) versus Endoscopic Variceal Ligation alone in secondary prophylaxis of variceal bleeding: a prospective randomized controlled trial. Am J Gastroenterol 2006; 101: S179.
  • 34
    Jha SK, Kumar A, Sharma BC, Sarin SK. Endoscopic variceal ligation (EVL) plus propranolol (P) and isosorbide mononitrate (ISMN) versus EVL alone in secondary prophylaxis of variceal bleeding: a prospective RCT. Hepatology 2007; 46: 250A.
  • 35
    Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009; 137: 892901.
  • 36
    Lo GH, Chen WC, Chan HH, et al. A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 2009; 24: 9827.
  • 37
    Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 4615.
  • 38
    Lo GH, Lai KH, Cheng JS, et al. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 2001; 53: 57984.
  • 39
    Sollano JD, Chan MM, Babaran RP, Lira EL. Propranolol prevents rebleeding after variceal ligation. Gastrointest Endosc 2001; 53: AB143.
  • 40
    Spanish Cooperative Variceal Rebleeding HHLLU, Hospital Clinic, Barcelona, Spain. Multicenter RCT comparing drug therapy vs the combination of drug therapy + endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis. Hepatology 2006; 44: 202A3A.
  • 41
    Garcia-Pagan JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 52635.
  • 42
    Pérez-Paramo M, Muñoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 438.
  • 43
    Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: hemodynamic and non-hemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window of the disease. Gut 2012 [Epub ahead of print].
  • 44
    Krag A, Wiest R, Gluud LL. Reduced mortality with non-selective betablockers compared to banding is not related to prevention of bleeding or bleeding-related mortality: systematic review of randomized trials. J Hepatol 2011; 54: S72.
  • 45
    Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 55663.
  • 46
    Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 118993.
  • 47
    Senzolo M, Cholongitas E, Marelli L, Thalheimer U, Patch D, Burroughs AK. The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol. Am J Gastroenterol 2006; 101: 24367.
    Direct Link:
  • 48
    Thalheimer U, Bosch J, Patch D, Burroughs A. Improved survival with nonselective beta blockers. Hepatology 2008; 48: 20912.
  • 49
    Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 183541.
  • 50
    Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 327.
  • 51
    Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 101722.